{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-002757","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.225471+00:00","generated_at":"2026-06-20T07:16:32.494940+00:00","sec_items":["2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AgeX draws remaining $500K under Secured Note, reaches $13.16M max; issues 340K warrants at $0.735","bullets":["Borrowed final $500,000 on Jan 25, 2023, reaching the $13,160,000 maximum principal under the Secured Convertible Note with Juvenescence.","Outstanding principal due Feb 14, 2024; interest replaced by Origination Fee of 4% per draw plus additional 4% after 12-month draw period.","Will issue warrants for 340,136 shares of common stock at $0.735 per share to Juvenescence, subject to NYSE American listing approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-002757","json":"https://secwatch.observer/filing/0001493152-23-002757.json","markdown":"https://secwatch.observer/filing/0001493152-23-002757.md","text":"https://secwatch.observer/filing/0001493152-23-002757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223002757/0001493152-23-002757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223002757/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:16:32.494940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff1643f14cf639dd3cf08ac6d52b31c813d17942","claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited at 4% of the amount each draw of loan funds maturing February 14, 2024.","evidence_excerpt":"On January 25, 2023, AgeX borrowed the remaining $500,000 under the Secured Convertible Promissory Note (the “Secured Note”) dated as of February 14, 2022 with Juvenescence Limited (“Juvenescence”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223002757/0001493152-23-002757-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Rate","value":"4% of the amount each draw of loan funds"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}